metformin and Glycosuria studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Glycosuria: The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).

Research Excerpts

Excerpt	Relevance	Reference
"To examine the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor that lowers blood glucose by increasing urinary glucose excretion (UGE), on asymptomatic bacteriuria and urinary tract infections (UTIs)."	9.16	Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. ( Capuano, G; Nicolle, LE; Usiskin, K; Ways, K, 2012)
"Metformin vs placebo treatment of diabetic pigs (twice 1."	5.33	Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. ( Ackermans, M; Corbijn, H; Dekker, R; Koopmans, SJ; Mroz, Z; Sauerwein, H, 2006)
"Both single-dose and chronic empagliflozin treatment caused glycosuria during fasting (median, 7."	5.19	Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. ( Baldi, S; Broedl, UC; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Woerle, HJ, 2014)
"To examine the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor that lowers blood glucose by increasing urinary glucose excretion (UGE), on asymptomatic bacteriuria and urinary tract infections (UTIs)."	5.16	Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. ( Capuano, G; Nicolle, LE; Usiskin, K; Ways, K, 2012)
"Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia."	5.14	Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. ( Fiedorek, FT; List, JF; Morales, E; Tang, W; Woo, V, 2009)
" We examined the effects of SGLT2 inhibitor-dapagliflozin on insulin resistance, hepatic gluconeogenesis, hepatic injury and pancreatic ER stress in high-fat diet-induced obese rats."	3.91	Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. ( Chatsudthipong, V; Jaikumkao, K; Lungkaphin, A; Pongchaidecha, A; Swe, MT; Thongnak, L, 2019)
"Metformin treatment had no substantial influence on tofogliflozin efficacy."	2.80	A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. ( Beck, A; Beyer, U; Boerlin, V; Christ, AD; Ciorciaro, C; Cynshi, O; Ikeda, S; Kadowaki, T; Meyer, M; Takano, Y; Tanaka, R, 2015)
" Concomitant administration of metformin and RE was well tolerated with minimal hypoglycemia, no serious adverse events, and no increase in lactic acid."	2.78	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. ( Dobbins, RL; Hussey, EK; James, CD; Kapur, A; O'Connor-Semmes, R; Polli, JW; Rafferty, B; Tao, W, 2013)
"Weight gain was probably not due to an increase in food intake, while REE per lean body mass decreased, suggesting a role for increased efficiency in fuel usage due to improved glycaemic control."	2.73	Weight gain in type 2 diabetes mellitus. ( Adams-Huet, B; Jacob, AN; Raskin, P; Salinas, K, 2007)
" Mean initial dosage was 7."	2.64	Glipizide in the treatment of maturity-onset diabetes: a multi-centre, out-patient study. ( Fowler, LK, 1978)
"Metformin vs placebo treatment of diabetic pigs (twice 1."	1.33	Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. ( Ackermans, M; Corbijn, H; Dekker, R; Koopmans, SJ; Mroz, Z; Sauerwein, H, 2006)

Research

Studies (23)

Authors

Clinical Trials (15)

Trial Overview

Trial Outcomes

Change From Baseline in Fasting Plasma Glucose at Day 1

Timeframe	Studies, this research(%)	All Research%
pre-1990	8 (34.78)	18.7374
1990's	3 (13.04)	18.2507
2000's	4 (17.39)	29.6817
2010's	8 (34.78)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Swe, MT	1
Thongnak, L	1
Jaikumkao, K	1
Pongchaidecha, A	1
Chatsudthipong, V	1
Lungkaphin, A	1
Nauck, M	1
Del Prato, S	1
Hussey, EK	1
Kapur, A	1
O'Connor-Semmes, R	1
Tao, W	1
Rafferty, B	1
Polli, JW	1
James, CD	1
Dobbins, RL	1
Ferrannini, E	1
Muscelli, E	1
Frascerra, S	1
Baldi, S	1
Mari, A	1
Heise, T	1
Broedl, UC	1
Woerle, HJ	1
Rosenstock, J	1
Cefalu, WT	1
Lapuerta, P	1
Zambrowicz, B	1
Ogbaa, I	1
Banks, P	1
Sands, A	1
Ikeda, S	1
Takano, Y	1
Cynshi, O	1
Tanaka, R	1
Christ, AD	1
Boerlin, V	1
Beyer, U	1
Beck, A	1
Ciorciaro, C	1
Meyer, M	1
Kadowaki, T	1
Arafa, NM	1
Marie, MA	1
AlAzimi, SA	1
List, JF	1
Woo, V	1
Morales, E	1
Tang, W	1
Fiedorek, FT	1
Nicolle, LE	1
Capuano, G	1
Ways, K	1
Usiskin, K	1
Koopmans, SJ	1
Mroz, Z	1
Dekker, R	1
Corbijn, H	1
Ackermans, M	1
Sauerwein, H	1
Jacob, AN	1
Salinas, K	1
Adams-Huet, B	1
Raskin, P	1
Beales, PE	1
Giorgini, A	1
Annovazzi, A	1
Signore, A	1
Parlapiano, C	1
Pozzilli, P	1
Gougeon, R	1
Styhler, K	1
Morais, JA	1
Jones, PJ	1
Marliss, EB	1
Fowler, LK	1
Shenfield, GM	1
Bhalla, IP	1
Steel, JM	1
Duncan, LJ	1
Björntorp, P	1
Carlström, S	1
Fagerberg, SE	1
Hermann, LS	1
Holm, AG	1
Scherstén, B	1
Ostman, J	1
Boyd, K	1
Rogers, C	1
Boreham, C	1
Andrews, WJ	1
Hadden, DR	1
Velussi, M	1
Cernigoi, AM	1
Viezzoli, L	1
Caffau, C	1
Holman, RR	1
Turner, RC	1
Tattersall, RB	1
Beringer, A	1
Geyer, G	1
Sokopp, B	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects With Type 2 Diabetes Mellitus.[NCT00376038]	Phase 1	13 participants (Actual)	Interventional	2006-08-31	Completed
Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial[NCT03151343]	Phase 3	92 participants (Actual)	Interventional	2017-03-29	Completed
An Open-label, Phase II Study to Determine Acute (After the First Dose Administration) and Chronic (After 28 Days of Treatment) Effects of the Sodium-glucose Co-transporter-2 (SGLT-2) Inhibitor Empagliflozin (BI 10773) (25 mg Once Daily) on Pre and Postpr[NCT01248364]	Phase 2	91 participants (Actual)	Interventional	2010-11-30	Completed
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)[NCT02798744]	Phase 4	68 participants (Actual)	Interventional	2016-12-31	Completed
Comparative Effects of Empagliflozin Versus Glimepiride After 26-weeks of Treatment Add on Metformin on Myocardial Metabolic Rate of Glucose Estimated Through 18FDG-PET in Patients With Type 2 Diabetes[NCT04183868]	Phase 4	26 participants (Actual)	Interventional	2016-04-30	Completed
A Prospective, Randomized, Parallel-group, Adaptive Design Phase IIb/III, Multicenter Study, to Assess the Efficacy of Polychemotherapy for Inducing Remission of Newly Diagnosed Type 2 Diabetes.[NCT04271189]	Phase 2/Phase 3	180 participants (Anticipated)	Interventional	2020-09-01	Active, not recruiting
Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2018-07-07	Recruiting
Human SLC5A2 Deficiency and the Glucagon-Incretin Axis: A Pilot Study[NCT03965000]		10 participants (Anticipated)	Observational	2019-01-24	Recruiting
Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)[NCT03933956]	Phase 3	2 participants (Actual)	Interventional	2020-01-09	Terminated (stopped due to Study terminated owing to challenges posed by the COVID-19 situation.)
Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment[NCT02304081]	Phase 4	64 participants (Actual)	Interventional	2015-01-31	Completed
Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients[NCT03361098]	Phase 4	65 participants (Actual)	Interventional	2017-09-18	Completed
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of LX4211 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metfor[NCT01376557]	Phase 2	299 participants (Actual)	Interventional	2011-06-30	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Cont[NCT00263276]	Phase 2	389 participants (Actual)	Interventional	2005-12-31	Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]	Phase 3	104 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 [NCT00642278]	Phase 2	451 participants (Actual)	Interventional	2008-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 1 (NCT01248364)
Timeframe: Baseline and day 1

Change From Baseline in Fasting Plasma Glucose at Day 28

Intervention	mmol/L (Least Squares Mean)
T2DM Naive	0.20
T2DM Metformin	0.39
Impaired Glucose Tolerance	-0.96
Healthy Subjects	-0.47

"Change from baseline of Fasting Plasma glucose (FPG) 3 hours and 35 minutes before meal at day 28.~Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable" (NCT01248364)
Timeframe: Baseline and day 28

Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 1

Intervention	mmol/L (Least Squares Mean)
T2DM Naive	-1.02
T2DM Metformin	-0.79
Impaired Glucose Tolerance	-0.81

Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours. (NCT01248364)
Timeframe: 0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 1

Change From Baseline in Glucose Metabolism (Pre-meal and Postprandial Glucose), PPG iAUC 5h, at Day 28

Intervention	g/dL/h (Least Squares Mean)
T2DM Naive	-1.94
T2DM Metformin	-3.52
Impaired Glucose Tolerance	-5.49
Healthy Subjects	-9.20

"Change from baseline in the incremental area under the curve of postprandial plasma glucose from 0 to 5 hours (PPG iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal plasma glucose at 0 hours.~Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable." (NCT01248364)
Timeframe: 0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 28

Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 1

Intervention	g/dL/h (Least Squares Mean)
T2DM Naive	-0.71
T2DM Metformin	-0.40
Impaired Glucose Tolerance	-7.31

Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal. (NCT01248364)
Timeframe: 0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 1

Change From Baseline in Rate of Endogenous Glucose Production: AUC 5h, at Day 28

Intervention	g (Least Squares Mean)
T2DM Naive	3.28
T2DM Metformin	8.76
Impaired Glucose Tolerance	3.70
Healthy Subjects	9.22

"Change from baseline in the area under the curve of endogenous glucose production (EGP) from 0 to 5 hours (EGP AUC 5h) after meal.~Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable." (NCT01248364)
Timeframe: 0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after meal at baseline and day 28

Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 1

Intervention	g (Least Squares Mean)
T2DM Naive	1.89
T2DM Metformin	5.02
Impaired Glucose Tolerance	3.14

Change from baseline in rate of endogenous glucose production (EGP) fast after one dose (NCT01248364)
Timeframe: Baseline and day 1

Change From Baseline in Rate of Endogenous Glucose Production: Fast, at Day 28

Intervention	umol/kgFFM/min (Least Squares Mean)
T2DM Naive	4.21
T2DM Metformin	4.51
Impaired Glucose Tolerance	3.28
Healthy Subjects	1.10

"Change from baseline in rate of endogenous glucose production (EGP) fast after 28 days of treatment.~Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable." (NCT01248364)
Timeframe: Baseline and day 28

Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 1

Intervention	umol/kgFFM/min (Least Squares Mean)
T2DM Naive	2.79
T2DM Metformin	4.63
Impaired Glucose Tolerance	1.47

Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour. (NCT01248364)
Timeframe: 0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after drug administration at baseline and day 1

Change From Baseline in Rate of Endogenous Glucose Production: iAUC 5h, at Day 28

Intervention	g (Least Squares Mean)
T2DM Naive	-8.52
T2DM Metformin	-7.22
Impaired Glucose Tolerance	-3.75
Healthy Subjects	1.28

"Change from baseline in the incremental area under the curve of endogenous glucose production from 0 to 5 hours (EGP iAUC 5h), defined as the area under the curve of timepoints 0 to 5 hours after meal reduced by the pre-meal endogenous glucose production at 0 hour.~Note, healthy subjects only received a single dose of empa so assessments at day 28 are not applicable." (NCT01248364)
Timeframe: 0 minutes (min), 15min, 30min, 45min, 1hour (h), 1h 30min, 2h, 2h 30min, 3h, 3h 30min, 4h, 4h 30min and 5h after drug administration at baseline and day 28

Change From Baseline in Body Weight at Week 12

Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12

Change From Baseline in HbA1c to Week 12

Change From Baseline in Systolic Blood Pressure (SPB) at Week 12

Change From Baseline in Triglycerides at Week 12

Number of Participants Achieving a HbA1c Value of <7% at Week 12

Absolute Change in Body Weight From Baseline to Week 12

Intervention	g (Least Squares Mean)
T2DM Naive	-6.95
T2DM Metformin	-10.63
Impaired Glucose Tolerance	-0.49

Intervention	kg (Mean)
75 mg LX4211 qd	-0.995
200 mg LX4211 qd	-1.956
400 mg LX4211 qd	-1.848
200 mg LX4211 Bid	-2.477
Placebo qd	-0.395

Intervention	mg/dL (Mean)
75 mg LX4211 qd	-9.5
200 mg LX4211 qd	-17.4
400 mg LX4211 qd	-27.1
200 mg LX4211 Bid	-26.9
Placebo qd	2.2

Intervention	% change (Mean)
75 mg LX4211 qd	-0.42
200 mg LX4211 qd	-0.52
400 mg LX4211 qd	-0.92
200 mg LX4211 Bid	-0.80
Placebo qd	-0.09

Intervention	mm Hg (Mean)
75 mg LX4211 qd	-0.123
200 mg LX4211 qd	-3.878
400 mg LX4211 qd	-5.746
200 mg LX4211 Bid	-4.452
Placebo qd	-0.283

Intervention	mg/dL (Mean)
75 mg LX4211 qd	-16.2
200 mg LX4211 qd	6.6
400 mg LX4211 qd	-16.8
200 mg LX4211 Bid	-16.9
Placebo qd	-30.5

Intervention	participants (Number)
75 mg LX4211 qd	16
200 mg LX4211 qd	15
400 mg LX4211 qd	22
200 mg LX4211 Bid	17
Placebo qd	14

The table below shows the mean absolute change in body weight from Baseline to Week 12 for each treatment group. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Change in Fasting Plasma Glucose (FPG) From Baseline to Week 12

Intervention	kg (Mean)
Placebo	-0.78
Canagliflozin 50 mg Daily	-1.96
Canagliflozin 100 mg Daily	-2.25
Canagliflozin 200 mg Daily	-2.32
Canagliflozin 300 mg Daily	-2.88
Canagliflozin 300 mg Twice Daily	-2.87
Sitagliptin 100 mg Daily	-0.43

The table below shows the mean change in FPG from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Change in HbA1c From Baseline to Week 12

Intervention	mmol/L (Mean)
Placebo	0.2
Canagliflozin 50 mg Daily	-0.9
Canagliflozin 100 mg Daily	-1.4
Canagliflozin 200 mg Daily	-1.5
Canagliflozin 300 mg Daily	-1.4
Canagliflozin 300 mg Twice Daily	-1.3
Sitagliptin 100 mg Daily	-0.7

The table below shows the mean change in HbA1c from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Change in Overnight Urine Glucose/Creatinine Ratio From Baseline to Week 12

Intervention	Percent (Mean)
Placebo	-0.22
Canagliflozin 50 mg Daily	-0.79
Canagliflozin 100 mg Daily	-0.76
Canagliflozin 200 mg Daily	-0.70
Canagliflozin 300 mg Daily	-0.92
Canagliflozin 300 mg Twice Daily	-0.95
Sitagliptin 100 mg Daily	-0.74

The table below shows the mean change in overnight urine glucose/creatinine ratio from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Percent Change in Body Weight From Baseline to Week 12

Intervention	mg/mg (Mean)
Placebo	1.9
Canagliflozin 50 mg Daily	35.4
Canagliflozin 100 mg Daily	51.5
Canagliflozin 200 mg Daily	50.5
Canagliflozin 300 mg Daily	49.4
Canagliflozin 300 mg Twice Daily	61.6
Sitagliptin 100 mg Daily	-1.9

The table below shows the mean percent change in body weight from Baseline to Week 12 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin or sitagliptin group minus placebo) in the least-squares mean change. (NCT00642278)
Timeframe: Day 1 (Baseline) and Week 12

Percentage of Patients With Symptoms of Hypoglycemia

Intervention	Percent change (Mean)
Placebo	-1.1
Canagliflozin 50 mg Daily	-2.3
Canagliflozin 100 mg Daily	-2.6
Canagliflozin 200 mg Daily	-2.7
Canagliflozin 300 mg Daily	-3.4
Canagliflozin 300 mg Twice Daily	-3.4
Sitagliptin 100 mg Daily	-0.6

The table below shows the percentage of patients who experienced symptomatic hypoglycemic events between Baseline and Week 12. (NCT00642278)
Timeframe: Up to Week 12

Article	Year
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC pharmacology & toxicology, 2013, Apr-30, Volume: 14 Topics: Adult; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycosuria;	2013
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. The Journal of clinical investigation, 2014, Volume: 124, Issue:2 Topics: Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; Body Mass Index; Calorimetry; Diabetes	2014
Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes care, 2015, Volume: 38, Issue:3 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Adm	2015
A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2015, Volume: 17, Issue:10 Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Combined Modality The	2015
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Diuretics;	2009
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Current medical research and opinion, 2012, Volume: 28, Issue:7 Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; G	2012
Weight gain in type 2 diabetes mellitus. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:3 Topics: Adipose Tissue; Adult; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combi	2007
Glipizide in the treatment of maturity-onset diabetes: a multi-centre, out-patient study. Current medical research and opinion, 1978, Volume: 5, Issue:5 Topics: Adult; Aged; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Female; Glipiz	1978
Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy. Diabetes research (Edinburgh, Scotland), 1992, Volume: 19, Issue:2 Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glybu	1992

Article	Year
Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats. Clinical science (London, England : 1979), 2019, 12-12, Volume: 133, Issue:23 Topics: Animals; Benzhydryl Compounds; Blood Glucose; Diet, High-Fat; Endoplasmic Reticulum Stress; Gluconeo	2019
[SGLT-2-inhibitor dapagliflozin: new treatment approach for diabetes type 2--new achievements, but also new questions!]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138 Suppl 1 Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Glipizide; Glucosides; Glycated Hemoglobin; Glycosu	2013
Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model. Chemico-biological interactions, 2016, Oct-25, Volume: 258 Topics: Acetylcholinesterase; Amino Acids; Animals; Biogenic Monoamines; Blood Glucose; Canagliflozin; Cereb	2016
Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism: clinical and experimental, 2006, Volume: 55, Issue:7 Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Eating; Glucose; Glycosuria; Hy	2006
Metformin does not alter diabetes incidence in the NOD mouse. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1997, Volume: 29, Issue:6 Topics: Aging; Animals; Blood Glucose; Diabetes Mellitus, Type 1; Female; Glycosuria; Hypoglycemic Agents; I	1997
Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes. Diabetes care, 2000, Volume: 23, Issue:1 Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combinati	2000
Metformin in the treatment of obese diabetics. The Practitioner, 1977, Volume: 219, Issue:1313 Topics: Diabetes Mellitus; Female; Glycosuria; Humans; Hyperglycemia; Male; Metformin; Obesity	1977
Influence of phenformin and metformin on exercise induced lactataemia in patients with diabetes mellitus. Diabetologia, 1978, Volume: 15, Issue:2 Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Glycosuria; Humans; Lactates; Male; Metformin	1978
[Median-term (4 months) treatment with glibenclamide + metformin substituting for glibenclamide + fenformin lowers the lacticemia levels in type-2 diabetics (NIDDM)]. La Clinica terapeutica, 1992, Volume: 141, Issue:12 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Drug Therapy, Combination; Female;	1992
Optimizing blood glucose control in type 2 diabetes: an approach based on fasting blood glucose measurements. Diabetic medicine : a journal of the British Diabetic Association, 1988, Volume: 5, Issue:6 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Fasting; Glycosuria; Humans; Hypoglycemic	1988
Mild familial diabetes with dominant inheritance. The Quarterly journal of medicine, 1974, Volume: 43, Issue:170 Topics: Acetohexamide; Adolescent; Adult; Aged; Blood Glucose; Carbohydrates; Child; Chlorpropamide; Diabete	1974
[Oral antidiabetic therapy with delayed-action glibenclamide and phenformin in fixed combination]. Minerva medica, 1974, Sep-01, Volume: 65, Issue:60 Topics: Adult; Aged; Blood Glucose; Carbutamide; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus	1974
Diabetes mellitus--refractory obesity. British medical journal, 1972, Jul-15, Volume: 3, Issue:5819 Topics: Biguanides; Diabetes Mellitus; Diet Therapy; Female; Fetal Death; Glucose Tolerance Test; Glycosuria	1972
[Influence of 3,5-dimethylisoxazol short-term administration on the carbohydrate metabolism in elderly diabetics with secondary failure of sulfonylurea treatment]. Wiener klinische Wochenschrift, 1969, Oct-08, Volume: 81, Issue:40 Topics: Aged; Blood Glucose; Carbohydrate Metabolism; Diabetes Mellitus; Fatty Acids, Nonesterified; Female;	1969

metformin and Glycosuria